ONCY announces Pelareorep ≥50% ORR & mPFS Improvements 31% week-16 overall response rate and 9.6-month median progression-free survival with pelareorep plus paclitaxel vs. 20% and 6.4 months with paclitaxel alone as of Oct. 2022 ASCO abstract cut-off date.
https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-positive-randomized-phase-2-data-from-bracelet-1-metastatic-breast-cancer-trial-demonstrating-pelareorep-drives-50-improvements-in-orr-and-mpfs-in-an-asco-annual-meeting-abstract-301835201.html